Find and Pitch Jounalists, Get Your Story Covered

Tags: breast cancer,breast cancer brain metastases ,recurrent glioblastoma multiforme ,antibody drug conjugates ,Trop-2

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	FDA grants Orphan Drug Designation to Ariceum cancer therapy - 18 days ago CatalYm shows potential of visugromab for treating cachexia - 3 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic Tumors - 18 days ago FDA Approves Zanidatamab for Biliary Tract Cancer - 3 months ago Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 5 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 6 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 6 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - over 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - about 2 months ago FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease - 3 months ago Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 5 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 6 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 8 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 11 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 12 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 12 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - over 1 year ago
4	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer - about 2 months ago Sequencing in Advanced Urothelial Carcinoma - 4 months ago Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-Changing? - 8 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - about 1 year ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - about 1 year ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - about 1 year ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer - over 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer - 2 months ago SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer - 2 months ago FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - 6 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 11 months ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study - 3 months ago FDA Approves Axatilimab-csfr for cGVHD - 6 months ago FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 11 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 12 months ago
7	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 4 months ago
8	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 11 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - about 1 year ago
10	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - about 1 year ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - about 1 year ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - about 1 year ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - about 1 year ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - about 1 year ago

Journalists covering sacituzumab